OTCM
WPDPF
Market cap0kUSD
, Last price
USD
Name
WPD Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
39.57%
Rev. gr., 5y
%
Revenues
0k
Net income
-80k
L
CFO
-205k
L-91.89%
Profile
WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat central nervous system tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of glioblastoma multiforme that is in the pre-clinical trial; and Annamycin to treat acute myeloid leukemia (AML) and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
IPO date
May 26, 2008
Employees
19
Domiciled in
CA
Incorporated in
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑01 | 2018‑01 | 2017‑01 | 2016‑01 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 269 | 1,704 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (269) | (1,704) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | (269) | (1,704) | |||||||
Net income | (80) -102.81% | 2,846 -164.01% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 371 | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | 304 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (6) | (18) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (205) | (2,530) | |||||||
CAPEX | (27) | ||||||||
Cash from investing activities | (176) | ||||||||
Cash from financing activities | 267 | 904 | |||||||
FCF | (146) | (3,734) | |||||||
| Balance | |||||||||
Cash | 86 | 18 | |||||||
Long term investments | 224 | ||||||||
Excess cash | 310 | 18 | |||||||
Stockholders' equity | (559) | (353) | |||||||
Invested Capital | 307 | ||||||||
ROIC | |||||||||
ROCE | 106.68% | 482.56% | |||||||
| EV | |||||||||
Common stock shares outstanding | 113,438 | 113,438 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (269) | (1,686) | |||||||
EV/EBITDA | |||||||||
Interest | 40 | 168 | |||||||
Interest/NOPBT | |||||||||